Clearside Biomedical Inc

NASDAQ:CLSD   4:00:00 PM EDT
1.20
+0.02 (+1.70%)
4:00:16 PM EDT: $1.20 0.00 (0.00%)
Products, Regulatory, Earnings Announcements

Clearside Biomedical Announces Positive Results In Oasis Phase 1/2A Clinical Trial Of Suprachoroidal Cls-Ax In Wet AMD Patients

Published: 11/09/2022 13:05 GMT
Clearside Biomedical Inc (CLSD) - Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2a Clinical Trial of Suprachoroidal Cls-ax (axitinib Injectable Suspension) in Wet Amd Patients.
Clearside Biomedical -primary Safety Endpoint Achieved at All Timepoints With All Doses Well-tolerated, No Treatment Related Or Serious Adverse Events.
Clearside Biomedical Inc - Final 6-month Data From Extension Study Expected in Q1 2023.
Clearside Biomedical Inc - Expect to Initiate Phase 2 Clinical Trial in Q1 2023.
Clearside Biomedical Inc - Cohorts 3, 4 Showed Promising Signs of Durability, Biologic Effect, and a Meaningful Reduction in Treatment Burden in Study.
Revenue is expected to be $0.12 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $0.07 Million
Next Quarter EPS Guidance is expected to be -$0.13

More details on our Analysts Page.